新股消息 | 諾輝健康一手入場費約13464.33港元,引入景順、清池資本、博裕、GIC等16家基石投資者
根據彭博新聞社獲悉的交易條款,諾輝健康計劃在香港首次公開募股(IPO)中以每股22.70港元-26.66港元的價格發行大約7,660萬股股份,籌集最多2.63億美元資金。
港媒報道稱,一手500股,入場費約13464.33港元。
週四開始接受機構投資者認購,計劃於2月10日確定發行價。
公司計劃股票於2月18日正式掛牌。
此次發行吸引了16家基石投資者,包括景順、清池資本、博裕、GIC等,其承諾的認購額合計達到1.24億美元。
高盛和瑞銀是這筆IPO的聯席保薦人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.